comparemela.com

Latest Breaking News On - Etripamil - Page 1 : comparemela.com

Effective Nasal Spray Therapy for Recurrent Abnormal Heart Rhythms

Etripamil nasal spray, self-administered at home, was found to relieve recurrent rapid abnormal heart rhythms.

United statesNew yorkJames ipPresbyterian weill cornell medical centerMilestone pharmaceuticalsNasal sprayWeill cornell medicineWeill cornell medical centerRapid heart rhythmsAbnormal heart rhythmsNasal spray

Etripamil Nasal Spray Outperforms Placebo for AFib with Rapid Ventricular Rate

In the phase 2 ReVeRA trial, etripamil nasal spray provided a marked reduction in ventricular rates among patients with atrial fibrillation and rapid ventricular rates.

United kingdomUnited statesCity ofA john cammAmerican heart association scientific sessionsClinical sciences research instituteCardiology clinical academic groupMilestone pharmaceuticals incMilestone pharmaceuticalsGeorge universityBritish heart foundation emeritus professorClinical cardiologyRevera phaseEtripamil nasal sprayNasal spray for afibAtrial fibrillation

#VisualAbstract: Intranasal etripamil effective for conversion of paroxysmal supraventricular tachycardia

Click to read the study in The Lancet ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Minute medicine incSupraventricular tachycardia

Intranasal etripamil effective for conversion of paroxysmal supraventricular tachycardia

1. Median time to sinus conversion was 17.2 minutes in the etripamil group versus 53.5 minutes in the placebo group. 2. Twice as many patients in the etripamil group converted to sinus rhythm than placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Symptomatic supraventricular tachycardia (SVT) can cause severe distress to patients. Current management includes

United statesRating levelBetween octCalcium channel blocker ccbIntranasal etripamilParoxysmal supraventricular tachycardiaSupraventricular tachycardiaChronic disease

Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update

- NDA submission for etripamil in patients with PSVT currently on track for 3Q23 - Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on. | May 11, 2023

United statesJoseph olivetoSethhz fischerDavid pittsVivus incExchange commissionProgram updatesSpectrum pharmaceuticals incMilestone pharmaceuticalsCordis corporationSociety for health economicsCenters for diseaseCompany board of directorsUs securities exchange commissionAgile therapeutics incMilestone pharmaceuticals inc

vimarsana © 2020. All Rights Reserved.